Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.

Rodolfo Bordoni,Fortunato Ciardiello,Joachim von Pawel,Diego Cortinovis,Thomas Karagiannis,Marcus Ballinger,Alan Sandler,Wei Yu,Pei He,Christina Matheny,Federico Felizzi,Achim Rittmeyer

Clinical Lung Cancer（2018）

引用 56|浏览32

暂无评分

摘要

These PRO data support the clinical benefit of atezolizumab in patients with previously treated advanced or metastatic NSCLC. Atezolizumab prolonged the TTD of patients' limitations in role and physical functions compared with docetaxel.

查看译文

关键词

Health-related quality of life,Immune checkpoint inhibitor,Immunotherapy,Patient-reported outcomes,PD-L1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要